Related Experiment Video

Updated: Jun 20, 2026

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

[Biomarkers in heart failure: BNP and NT-proBNP]

Chao-Chung Ho1, Chuan-Chieh Liu

  • 1Department of Nursing, Chang Gung Institute of Technology.

Hu Li Za Zhi the Journal of Nursing
|September 18, 2009
PubMed

Insights

B-type natriuretic peptide (BNP) and NT-proBNP are key heart failure (HF) biomarkers. While valuable, additional biomarkers are needed for improved HF diagnosis and treatment.

Area of Science:

  • Biomarkers and Molecular Diagnostics
  • Cardiovascular Medicine

Context:

  • Heart failure (HF) incidence has risen significantly, posing a major public health challenge.
  • High readmission rates for acute decompensated HF underscore the need for better patient monitoring and therapeutic guidance.
  • Molecular biomarkers are crucial for understanding and managing HF.

Purpose:

  • To evaluate the role of natriuretic peptides, specifically B-type natriuretic peptide (BNP) and NT-proBNP, as diagnostic and prognostic tools in heart failure.
  • To identify the limitations of current biomarkers and highlight the need for novel markers.

Summary:

  • BNP and NT-proBNP are established biomarkers for heart failure (HF), aiding in diagnosis and prognosis.
  • Despite their utility, BNP and NT-proBNP do not meet all criteria for an ideal biomarker.
  • The development of new biomarkers is essential for advancing the diagnosis and treatment of both chronic and acute decompensated HF.

Impact:

  • BNP and NT-proBNP serve as critical indicators in cardiovascular disorders, particularly heart failure.
  • The findings emphasize the ongoing search for superior biomarkers to enhance HF management.
  • Future biomarker discovery promises to improve patient outcomes and therapeutic strategies for heart failure.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...